Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Nanog overexpression enhances the therapeutic efficacy of ADMSCs in AMI rats via the upregulation of JAK/STAT3 signaling and cyclin-mitochondrial expression.

Yen HT., Huang DKR., Lan XW., Yeh JN., Chen YL., Huang CR.

Animal Study with a reported sample of 50 on Cardiovascular Disease, Chronic Wound, published in Int J Biol Sci (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int J Biol Sci (2025)
Country
Australia
Reported sample size
50
Source database
PubMed
PMID
40765818
PMCID
PMC12320234
DOI
10.7150/ijbs.112824
Citations
1

Abstract (original English)

Background: This study investigated whether Nanog-overexpressing adipose-derived mesenchymal stem cells (Nanog OE -ADMSCs) are superior to unmodified ADMSCs in improving the left ventricular ejection fraction (LEVF) in acute myocardial infarction (AMI) patients. Methods: We utilized silencing and overexpression of Nanog gene in ADMSCs and performed a wound healing assay/transwell migration assay/MTT cell viability assay/left coronary artery ligation for AMI induction. Additionally, we categorized the cells into three classes [i.e., (ADMSCs and Nanog OE -ADMSCs); A 1 (ADMSCs)/A 2 (ADMSCs + CoCl 2 )/A 3 (Nanog OE -ADMSCs + CoCl 2 )/A 4 (siRNA-Nanog-ADMSCs) + CoCl 2 ); B 1 (ADMSCs)/B 2 (ADMSCs + H 2 O 2 )/B 3 (Nanog OE -ADMSCs + H 2 O 2 )/B 4 (siRNA-Nanog gene in ADMSCs + H 2 O 2 )], and the rats (n=50) were evenly divided into Groups 1 (sham-operated control)/2 (AMI)/3 (AMI+ADMSCs)/4 (AMI+Nanog OE -ADMSCs)/5 (AMI+siRNA-Nanog-ADMSCs). The hearts were harvested on Day 35. Results: In vitro experiments revealed significantly higher ATP, relative mitochondrial DNA/Nonog gene expression, mitochondrial cytochrome C+ cell, angiogenesis and exosome-specific marker (Alix/CD81/CD63/CD9) levels in Nanog OE -ADMSCs than in ADMSCs. The cell viability, wound healing, and migration were highest in A1, lowest in A4, and significantly greater in A3 than in A2, whereas early/late apoptosis and int

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMyocardial InfarctionRatsSTAT3 Transcription FactorMesenchymal Stem CellsNanog Homeobox ProteinSignal TransductionMaleRats, Sprague-DawleyMitochondria

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research